Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cephalothin + tobramycin
- Development stage
- Unknown
- Lead developer
- Eli Lilly
- Modality
- Small Molecules
- Administration
- Intravenous, Intramuscular
01
Overview
Cephalothin + tobramycin is an antibiotic combination therapy that pairs a first-generation cephalosporin (cephalothin) with an aminoglycoside (tobramycin). Cephalothin inhibits bacterial cell wall synthesis while tobramycin inhibits bacterial protein synthesis. This combination provides broad-spectrum coverage against both Gram-positive and Gram-negative bacteria, including Pseudomonas aeruginosa. It is used for serious infections such as sepsis, meningitis, respiratory tract infections, intra-abdominal infections, skin infections, bone infections, and complicated urinary tract infections.
02
Targets
Beyond the preview
Go deeper on cephalothin + tobramycin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cephalothin + tobramycin.